The oligonucleotide synthesis services market size has grown strongly in recent years. It will grow from $2.93 billion in 2025 to $3.21 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to growth in pcr and sequencing use, expansion of molecular biology research, rise in genomic testing, increase in academic genomics funding, expansion of biotech r and d activity.
The oligonucleotide synthesis services market size is expected to see strong growth in the next few years. It will grow to $4.7 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to growth of gene and cell therapy pipelines, rising crispr and gene editing demand, expansion of nucleic acid therapeutics, increased precision diagnostics use, scale up of clinical oligo production. Major trends in the forecast period include high throughput custom oligo production, modified and labeled oligonucleotide services, gmp grade oligo manufacturing, rapid turnaround gene editing oligos, advanced oligo purification workflows.
The increasing focus on personalized medicine is anticipated to drive the growth of the oligonucleotide synthesis services market in the coming years. Personalized medicine refers to a medical approach that customizes treatment and prevention strategies based on an individual’s genetic, biological, and lifestyle characteristics. The adoption of personalized medicine is rising due to advances in genomics and molecular diagnostics, which enable treatments to be tailored to an individual’s genetic profile for improved outcomes. Oligonucleotide synthesis services support personalized medicine by enabling rapid and precise production of custom DNA or RNA sequences used in patient-specific diagnostics, targeted therapies, and gene-based treatments, facilitating interventions tailored to a patient’s genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine is driving the growth of the oligonucleotide synthesis services market.
Companies operating in the oligonucleotide synthesis services market are focusing on developing DNA and RNA production capabilities to support therapeutic and diagnostic research. DNA and RNA production capabilities involve advanced methods for creating and scaling high-quality genetic material, which play a crucial role in enabling research, diagnostics, and the development of biopharmaceutical therapies. For example, in May 2025, Oligo Factory Inc., a US-based manufacturing company, launched a low-scale oligo synthesis capability to broaden support for therapeutic and diagnostic researchers and developers. It enables small-batch custom DNA/RNA production starting at 50 nmol for early research and development in therapeutics, diagnostics, qPCR, NGS, and preclinical studies. It cuts costs and waste, delivers quick turnaround (four weeks or less) with GMP or ISO 13485 quality, and supports seamless scaling without vendor changes via portfolios such as FactorTx. This agility benefits researchers needing prototypes over large minimums.
In September 2023, Bioserve Biotechnologies (India) Pvt Ltd, an India-based biotechnology company offering oligonucleotide synthesis services, partnered with BioMavericks Ltd. to expand the distribution and marketing of its molecular biology products across the United Kingdom. Through this partnership, Bioserve aims to increase the availability of its DNA oligonucleotide synthesis offerings, improve customer support, and accelerate adoption in research and diagnostic applications. BioMavericks Ltd. is a UK-based biotech startup leveraging AI technology to discover early-stage biomarkers for cancer diagnostics.
Major companies operating in the oligonucleotide synthesis services market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., QIAGEN N.V., Integrated DNA Technologies Inc., Sangon Biotech (Shanghai) Co. Ltd., Ajinomoto Co. Inc., Twist Bioscience Corporation, Sigma-Aldrich Co. LLC, Aldevron LLC, Bioneer Corporation, GenScript Biotech Corporation, BBI Life Sciences Ltd., Takara Bio Inc., BioServe Biotechnologies Ltd., Eurofins Genomics Germany GmbH, Bio-Synthesis Inc., TriLink BioTechnologies LLC, BioBasic Inc., Biosearch Technologies Inc., JenaBioscience GmbH, Geneworks Pty Ltd., HUWEL Life Science Co. Ltd., and SynoLigo Pvt. Ltd.
Tariffs on specialty reagents, phosphoramidites, and laboratory chemicals are increasing input costs in the oligonucleotide synthesis services market. High purity and modified oligonucleotide segments that depend on imported synthesis reagents are most affected. Research and therapeutic oligo production centers in north america and europe face higher procurement expenses. These added costs can extend project budgets and reduce small lab outsourcing volumes. At the same time, tariffs are encouraging regional reagent manufacturing and localized synthesis capacity expansion.
The oligonucleotide synthesis services market research report is one of a series of new reports that provides oligonucleotide synthesis services market statistics, including oligonucleotide synthesis services industry global market size, regional shares, competitors with a oligonucleotide synthesis services market share, detailed oligonucleotide synthesis services market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide synthesis services industry. This oligonucleotide synthesis services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oligonucleotide synthesis services are specialized laboratory services that design and chemically produce short, custom DNA or RNA sequences (oligonucleotides) tailored to specific research, diagnostic, or therapeutic needs. These services provide high-purity, sequence-verified oligos in different scales and modifications for applications including PCR, gene editing, sequencing, molecular diagnostics, and drug development.
The major types of oligonucleotides in oligonucleotide synthesis services include deoxyribonucleic acid (DNA) oligonucleotides, ribonucleic acid (RNA) oligonucleotides, peptide nucleic acids (PNAs), locked nucleic acids (LNAs), and other synthetic nucleotides. DNA oligonucleotides are short DNA sequences synthesized for use in research, diagnostics, and therapeutic applications. These services are delivered through methods such as solid-phase synthesis, liquid-phase synthesis, microarray-based synthesis, automated synthesizers, and enzymatic synthesis. They are offered at various purity levels, including standard, high, ultra-high, and custom purities, along with quality control measures. Applications include diagnostics, therapeutics, research and development, gene editing, and vaccine development, with end users such as academic and research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, contract research organizations (CROs), and clinical laboratories.
The oligonucleotide synthesis services market includes revenues earned by entities through custom oligonucleotide synthesis, scale-up synthesis services, purification and quality control, sequence verification services, modified oligonucleotide synthesis, conjugation and labeling services, assay development support, regulatory compliance support, laboratory consultation services, and analytical testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The oligonucleotide synthesis services market size is expected to see strong growth in the next few years. It will grow to $4.7 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to growth of gene and cell therapy pipelines, rising crispr and gene editing demand, expansion of nucleic acid therapeutics, increased precision diagnostics use, scale up of clinical oligo production. Major trends in the forecast period include high throughput custom oligo production, modified and labeled oligonucleotide services, gmp grade oligo manufacturing, rapid turnaround gene editing oligos, advanced oligo purification workflows.
The increasing focus on personalized medicine is anticipated to drive the growth of the oligonucleotide synthesis services market in the coming years. Personalized medicine refers to a medical approach that customizes treatment and prevention strategies based on an individual’s genetic, biological, and lifestyle characteristics. The adoption of personalized medicine is rising due to advances in genomics and molecular diagnostics, which enable treatments to be tailored to an individual’s genetic profile for improved outcomes. Oligonucleotide synthesis services support personalized medicine by enabling rapid and precise production of custom DNA or RNA sequences used in patient-specific diagnostics, targeted therapies, and gene-based treatments, facilitating interventions tailored to a patient’s genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine is driving the growth of the oligonucleotide synthesis services market.
Companies operating in the oligonucleotide synthesis services market are focusing on developing DNA and RNA production capabilities to support therapeutic and diagnostic research. DNA and RNA production capabilities involve advanced methods for creating and scaling high-quality genetic material, which play a crucial role in enabling research, diagnostics, and the development of biopharmaceutical therapies. For example, in May 2025, Oligo Factory Inc., a US-based manufacturing company, launched a low-scale oligo synthesis capability to broaden support for therapeutic and diagnostic researchers and developers. It enables small-batch custom DNA/RNA production starting at 50 nmol for early research and development in therapeutics, diagnostics, qPCR, NGS, and preclinical studies. It cuts costs and waste, delivers quick turnaround (four weeks or less) with GMP or ISO 13485 quality, and supports seamless scaling without vendor changes via portfolios such as FactorTx. This agility benefits researchers needing prototypes over large minimums.
In September 2023, Bioserve Biotechnologies (India) Pvt Ltd, an India-based biotechnology company offering oligonucleotide synthesis services, partnered with BioMavericks Ltd. to expand the distribution and marketing of its molecular biology products across the United Kingdom. Through this partnership, Bioserve aims to increase the availability of its DNA oligonucleotide synthesis offerings, improve customer support, and accelerate adoption in research and diagnostic applications. BioMavericks Ltd. is a UK-based biotech startup leveraging AI technology to discover early-stage biomarkers for cancer diagnostics.
Major companies operating in the oligonucleotide synthesis services market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., QIAGEN N.V., Integrated DNA Technologies Inc., Sangon Biotech (Shanghai) Co. Ltd., Ajinomoto Co. Inc., Twist Bioscience Corporation, Sigma-Aldrich Co. LLC, Aldevron LLC, Bioneer Corporation, GenScript Biotech Corporation, BBI Life Sciences Ltd., Takara Bio Inc., BioServe Biotechnologies Ltd., Eurofins Genomics Germany GmbH, Bio-Synthesis Inc., TriLink BioTechnologies LLC, BioBasic Inc., Biosearch Technologies Inc., JenaBioscience GmbH, Geneworks Pty Ltd., HUWEL Life Science Co. Ltd., and SynoLigo Pvt. Ltd.
Tariffs on specialty reagents, phosphoramidites, and laboratory chemicals are increasing input costs in the oligonucleotide synthesis services market. High purity and modified oligonucleotide segments that depend on imported synthesis reagents are most affected. Research and therapeutic oligo production centers in north america and europe face higher procurement expenses. These added costs can extend project budgets and reduce small lab outsourcing volumes. At the same time, tariffs are encouraging regional reagent manufacturing and localized synthesis capacity expansion.
The oligonucleotide synthesis services market research report is one of a series of new reports that provides oligonucleotide synthesis services market statistics, including oligonucleotide synthesis services industry global market size, regional shares, competitors with a oligonucleotide synthesis services market share, detailed oligonucleotide synthesis services market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide synthesis services industry. This oligonucleotide synthesis services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oligonucleotide synthesis services are specialized laboratory services that design and chemically produce short, custom DNA or RNA sequences (oligonucleotides) tailored to specific research, diagnostic, or therapeutic needs. These services provide high-purity, sequence-verified oligos in different scales and modifications for applications including PCR, gene editing, sequencing, molecular diagnostics, and drug development.
The major types of oligonucleotides in oligonucleotide synthesis services include deoxyribonucleic acid (DNA) oligonucleotides, ribonucleic acid (RNA) oligonucleotides, peptide nucleic acids (PNAs), locked nucleic acids (LNAs), and other synthetic nucleotides. DNA oligonucleotides are short DNA sequences synthesized for use in research, diagnostics, and therapeutic applications. These services are delivered through methods such as solid-phase synthesis, liquid-phase synthesis, microarray-based synthesis, automated synthesizers, and enzymatic synthesis. They are offered at various purity levels, including standard, high, ultra-high, and custom purities, along with quality control measures. Applications include diagnostics, therapeutics, research and development, gene editing, and vaccine development, with end users such as academic and research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, contract research organizations (CROs), and clinical laboratories.
The oligonucleotide synthesis services market includes revenues earned by entities through custom oligonucleotide synthesis, scale-up synthesis services, purification and quality control, sequence verification services, modified oligonucleotide synthesis, conjugation and labeling services, assay development support, regulatory compliance support, laboratory consultation services, and analytical testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Oligonucleotide Synthesis Services Market Characteristics
3. Oligonucleotide Synthesis Services Market Supply Chain Analysis
4. Global Oligonucleotide Synthesis Services Market Trends and Strategies
5. Oligonucleotide Synthesis Services Market Analysis Of End Use Industries
7. Global Oligonucleotide Synthesis Services Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Oligonucleotide Synthesis Services Total Addressable Market (TAM) Analysis for the Market
9. Oligonucleotide Synthesis Services Market Segmentation
10. Oligonucleotide Synthesis Services Market Regional and Country Analysis
11. Asia-Pacific Oligonucleotide Synthesis Services Market
12. China Oligonucleotide Synthesis Services Market
13. India Oligonucleotide Synthesis Services Market
14. Japan Oligonucleotide Synthesis Services Market
15. Australia Oligonucleotide Synthesis Services Market
16. Indonesia Oligonucleotide Synthesis Services Market
17. South Korea Oligonucleotide Synthesis Services Market
18. Taiwan Oligonucleotide Synthesis Services Market
19. South East Asia Oligonucleotide Synthesis Services Market
20. Western Europe Oligonucleotide Synthesis Services Market
21. UK Oligonucleotide Synthesis Services Market
22. Germany Oligonucleotide Synthesis Services Market
23. France Oligonucleotide Synthesis Services Market
24. Italy Oligonucleotide Synthesis Services Market
25. Spain Oligonucleotide Synthesis Services Market
26. Eastern Europe Oligonucleotide Synthesis Services Market
27. Russia Oligonucleotide Synthesis Services Market
28. North America Oligonucleotide Synthesis Services Market
29. USA Oligonucleotide Synthesis Services Market
30. Canada Oligonucleotide Synthesis Services Market
31. South America Oligonucleotide Synthesis Services Market
32. Brazil Oligonucleotide Synthesis Services Market
33. Middle East Oligonucleotide Synthesis Services Market
34. Africa Oligonucleotide Synthesis Services Market
36. Oligonucleotide Synthesis Services Market Competitive Landscape and Company Profiles
37. Oligonucleotide Synthesis Services Market Other Major and Innovative Companies
41. Oligonucleotide Synthesis Services Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Oligonucleotide Synthesis Services Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses oligonucleotide synthesis services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oligonucleotide synthesis services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oligonucleotide synthesis services market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type Of Oligonucleotide: Deoxyribonucleic Acid Oligonucleotides; Ribonucleic Acid Oligonucleotides; Peptide Nucleic Acids (PNAs); Locked Nucleic Acids (LNAs); Other Synthetic Nucleotides2) By Synthesis Method: Solid Phase Synthesis; Liquid Phase Synthesis; Microarray Based Synthesis; Oligonucleotide Synthesis Via Automated Synthesizers; Enzymatic Synthesis
3) By Purity Level: Standard Purity; High Purity; Ultra High Purity; Custom Purity Solutions; Quality Control Measures
4) By Application: Diagnostics; Therapeutics; Research and Development; Gene Editing; Vaccine Development
5) By End User: Academic and Research Institutions; Pharmaceutical and Biotechnology Companies; Diagnostic Laboratories; Contract Research Organizations (CROs); Clinical Laboratories
Subsegments:
1) By Deoxyribonucleic Acid Oligonucleotides: Standard Deoxyribonucleic Acid Oligonucleotides; Modified Deoxyribonucleic Acid Oligonucleotides; Phosphorothioate Deoxyribonucleic Acid Oligonucleotides; Methylated Deoxyribonucleic Acid Oligonucleotides2) By Ribonucleic Acid Oligonucleotides: Standard Ribonucleic Acid Oligonucleotides; Modified Ribonucleic Acid Oligonucleotides; Small Interfering Ribonucleic Acid Oligonucleotides; Micro Ribonucleic Acid Oligonucleotides
3) By Peptide Nucleic Acids: Standard Peptide Nucleic Acids; Modified Peptide Nucleic Acids; Functionalized Peptide Nucleic Acids
4) By Locked Nucleic Acids: Standard Locked Nucleic Acids; 2'-O-Methyl Locked Nucleic Acids; Gapmer Locked Nucleic Acids
5) By Other Synthetic Nucleotides: Morpholino Oligonucleotides; Phosphoramidite Oligonucleotides; Xeno Nucleic Acid Oligonucleotides; Synthetic Aptamers
Companies Mentioned: Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; QIAGEN N.V.; Integrated DNA Technologies Inc.; Sangon Biotech (Shanghai) Co. Ltd.; Ajinomoto Co. Inc.; Twist Bioscience Corporation; Sigma-Aldrich Co. LLC; Aldevron LLC; Bioneer Corporation; GenScript Biotech Corporation; BBI Life Sciences Ltd.; Takara Bio Inc.; BioServe Biotechnologies Ltd.; Eurofins Genomics Germany GmbH; Bio-Synthesis Inc.; TriLink BioTechnologies LLC; BioBasic Inc.; Biosearch Technologies Inc.; JenaBioscience GmbH; Geneworks Pty Ltd.; HUWEL Life Science Co. Ltd.; and SynoLigo Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Oligonucleotide Synthesis Services market report include:- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- QIAGEN N.V.
- Integrated DNA Technologies Inc.
- Sangon Biotech (Shanghai) Co. Ltd.
- Ajinomoto Co. Inc.
- Twist Bioscience Corporation
- Sigma-Aldrich Co. LLC
- Aldevron LLC
- Bioneer Corporation
- GenScript Biotech Corporation
- BBI Life Sciences Ltd.
- Takara Bio Inc.
- BioServe Biotechnologies Ltd.
- Eurofins Genomics Germany GmbH
- Bio-Synthesis Inc.
- TriLink BioTechnologies LLC
- BioBasic Inc.
- Biosearch Technologies Inc.
- JenaBioscience GmbH
- Geneworks Pty Ltd.
- HUWEL Life Science Co. Ltd.
- and SynoLigo Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | March 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.21 Billion |
| Forecasted Market Value ( USD | $ 4.7 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
